A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a
complication of transplantation where the donor graft attacks and damages some of your
tissues. After stem cell transplant, all patients receive prophylactic medications against
In this research study, we are studying the safety and effectiveness of a bortezomib based
GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call
transplantation from a matched unrelated donor, mismatched related or unrelated donor.